Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 U.S. compounding pharmacies industry 3600 synopsis, 2017 – 2030
Chapter 3 US Compounding Pharmacies Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 – 2030 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing geriatric population and improved longevity
3.3.1.2 Growing acceptance of personalized medicines in U.S.
3.3.1.3 Increasing drug shortage in the country
3.3.1.4 Convenience of using compounded drugs
3.3.1.5 Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women
3.3.2 Restraints
3.3.2.1 Issues related to safety standards of compounded drugs
3.3.2.2 Changing regulatory scenario
3.4 Growth potential analysis
3.4.1 By pharmacy type
3.4.2 By sterility
3.4.3 By product
3.4.4 By application
3.4.5 By compounding type
3.4.6 By therapeutic area
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.7 Reimbursement landscape
3.8 Porter's analysis
3.9 Competitive landscape, 2021
3.10 PESTEL analysis
Chapter 4 US Compounding Pharmacies Market, By Pharmacy Type
4.1 Key segment trends
4.2 503A
4.2.1 Market size, by 503A, 2017-2030 (USD Million)
4.3 503B
4.3.1 Market size, by 503B, 2017-2030 (USD Million)
Chapter 5 US Compounding Pharmacies Market, By Sterility
5.1 Key segment trends
5.2 Sterile
5.2.1 Market size, by sterile, 2017-2030 (USD Million)
5.3 Non-sterile
5.3.1 Market size, by non-sterile, 2017-2030 (USD Million)
Chapter 6 US Compounding Pharmacies Market, By Product
6.1 Key segment trends
6.2 Oral
6.2.1 Market size, by oral, 2017-2030 (USD Million)
6.2.2 Solid preparation
6.2.2.1 Market size, by solid preparation, 2017-2030 (USD Million)
6.2.2.2 Tablets
6.2.2.2.1 Market size, by tablets, 2017 - 2030 (USD Million)
6.2.2.3 Capsules
6.2.2.3.1 Market size, by capsules, 2017 - 2030 (USD Million)
6.2.2.4 Granules
6.2.2.4.1 Market size, by granules, 2017 - 2030 (USD Million)
6.2.2.5 Powder
6.2.2.5.1 Market size, by powder, 2017 - 2030 (USD Million)
6.2.2.6 Others
6.2.2.6.1 Market size, by others, 2017 - 2030 (USD Million)
6.2.3 Liquid preparation
6.2.3.1 Market size, by liquid preparation, 2017-2030 (USD Million)
6.2.3.2 Solutions
6.2.3.2.1 Market size, by solutions, 2017 - 2030 (USD Million)
6.2.3.3 Suspension
6.2.3.3.1 Market size, by suspension, 2017 - 2030 (USD Million)
6.2.3.4 Emulsion
6.2.3.4.1 Market size, by emulsion, 2017 - 2030 (USD Million)
6.2.3.5 Syrup
6.2.3.5.1 Market size, by syrup, 2017 - 2030 (USD Million)
6.2.3.6 Others
6.2.3.6.1 Market size, by others, 2017 - 2030 (USD Million)
6.2.4 Topical
6.2.4.1 Market size, by topical, 2017-2030 (USD Million)
6.2.4.2 Creams
6.2.4.2.1 Market size, by creams, 2017 - 2030 (USD Million)
6.2.4.3 Gels
6.2.4.3.1 Market size, by gels, 2017 - 2030 (USD Million)
6.2.4.4 Pastes
6.2.4.4.1 Market size, by pastes, 2017 - 2030 (USD Million)
6.2.4.5 Ointments
6.2.4.5.1 Market size, by ointments, 2017 - 2030 (USD Million)
6.2.4.6 Others
6.2.4.6.1 Market size, by others, 2017 - 2030 (USD Million)
6.2.5 Rectal
6.2.5.1 Market size, by rectal, 2017-2030 (USD Million)
6.2.5.2 Suppositories
6.2.5.2.1 Market size, by suppositories, 2017 - 2030 (USD Million)
6.2.5.3 Enemas
6.2.5.3.1 Market size, by enemas, 2017 - 2030 (USD Million)
6.2.5.4 Others
6.2.5.4.1 Market size, by others, 2017 - 2030 (USD Million)
6.2.6 Parenteral
6.2.6.1 Market size, by parenteral, 2017-2030 (USD Million)
6.2.6.2 Small volume parenteral (SVP) solutions
6.2.6.2.1 Market size, by small volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
6.2.6.3 Large volume parenteral (LVP) solutions
6.2.6.3.1 Market size, by large volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
6.2.7 Nasal
6.2.7.1 Market size, by nasal, 2017-2030 (USD Million)
6.2.8 Ophthalmic
6.2.8.1 Market size, by ophthalmic, 2017-2030 (USD Million)
6.2.9 Otic
6.2.9.1 Market size, by otic, 2017-2030 (USD Million)
Chapter 7 US Compounding Pharmacies Market, By Application
7.1 Key segment trends
7.2 Pediatric
7.2.1 Market size, by pediatric, 2017-2030 (USD Million)
7.3 Adult
7.3.1 Market size, by adult, 2017-2030 (USD Million)
7.4 Geriatric
7.4.1 Market size, by geriatric, 2017-2030 (USD Million)
7.5 Veterinary
7.5.1 Market size, by veterinary, 2017-2030 (USD Million)
Chapter 8 US Compounding Pharmacies Market, By Compounding Type
8.1 Key segment trends
8.2 Pharmaceutical Ingredient Alteration (PIA)
8.2.1 Market size, by pharmaceutical ingredient alteration (PIA), 2017-2030 (USD Million)
8.3 Currently Unavailable Pharmaceutical Manufacturing (CUPM)
8.3.1 Market size, by currently unavailable pharmaceutical manufacturing (CUPM), 2017-2030 (USD Million)
8.4 Pharmaceutical Dosage Alteration (PDA)
8.4.1 Market size, by pharmaceutical dosage alteration (PIA), 2017-2030 (USD Million)
8.5 Others
8.5.1 Market size, by others, 2017-2030 (USD Million)
Chapter 9 US Compounding Pharmacies Market, By Therapeutic Area
9.1 Key segment trends
9.2 Hormone replacement
9.2.1 Market size, by hormone replacement, 2017-2030 (USD Million)
9.3 Pain management
9.3.1 Market size, by pain management, 2017-2030 (USD Million)
9.4 Dermatology
9.4.1 Market size, by dermatology, 2017-2030 (USD Million)
9.5 Specialty drugs
9.5.1 Market size, by specialty drugs, 2017-2030 (USD Million)
9.6 Nutritional supplements
9.6.1 Market size, by nutritional supplements, 2017-2030 (USD Million)
9.7 Others
9.7.1 Market size, by others, 2017-2030 (USD Million)
Chapter 10 Company Profiles
10.1 Strategy dashboard, 2021
10.2 Athenex Pharma Solutions (Athenex Inc.)
10.2.1 Business overview
10.2.2 Financial data
10.2.3 Product landscape
10.2.4 Strategic outlook
10.2.5 SWOT analysis
10.3 B Braun Melsungen AG
10.3.1 Business overview
10.3.2 Financial data
10.3.3 Product landscape
10.3.4 SWOT analysis
10.4 Clinigen Group PLC
10.4.1 Business overview
10.4.2 Financial data
10.4.3 Product landscape
10.4.4 Strategic outlook
10.4.5 SWOT analysis
10.5 Dougherty’s Pharmacy, Inc.
10.5.1 Business overview
10.5.2 Financial data
10.5.3 Product landscape
10.5.4 SWOT analysis
10.6 Fagron
10.6.1 Business overview
10.6.2 Financial data
10.6.3 Product landscape
10.6.4 Strategic outlook
10.6.5 SWOT analysis
10.7 Fresenius Kabi
10.7.1 Business overview
10.7.2 Financial data
10.7.3 Product landscape
10.7.4 Strategic outlook
10.7.5 SWOT analysis
10.8 ImprimisRx (Harrow Health, Inc.)
10.8.1 Business overview
10.8.2 Financial data
10.8.3 Product landscape
10.8.4 Strategic outlook
10.8.5 SWOT analysis
10.9 Institutional Pharmacy Solutions
10.9.1 Business overview
10.9.2 Financial data
10.9.3 Product landscape
10.9.4 Strategic outlook
10.9.5 SWOT analysis
10.10 ITC Compounding Pharmacy
10.10.1 Business overview
10.10.2 Financial data
10.10.3 Product landscape
10.10.4 Strategic outlook
10.10.5 SWOT analysis
10.11 Lorraine’s Pharmacy
10.11.1 Business overview
10.11.2 Financial data
10.11.3 Product landscape
10.11.4 Strategic outlook
10.11.5 SWOT analysis
10.12 McGuff Company Inc (McGuff Compounding Pharmacy Services)
10.12.1 Business overview
10.12.2 Financial data
10.12.3 Product landscape
10.12.4 Strategic outlook
10.12.5 SWOT analysis
10.13 Nephron Pharmaceuticals Corporation
10.13.1 Business overview
10.13.2 Financial data
10.13.3 Product landscape
10.13.4 Strategic outlook
10.13.5 SWOT analysis
10.14 Pencol Compounding Pharmacy
10.14.1 Business overview
10.14.2 Financial data
10.14.3 Product landscape
10.14.4 Strategic outlook
10.14.5 SWOT analysis
10.15 QuVa Pharma
10.15.1 Business overview
10.15.2 Financial data
10.15.3 Product landscape
10.15.4 Strategic outlook
10.15.5 SWOT analysis
10.16 Rx3 Compounding Pharmacy
10.16.1 Business overview
10.16.2 Financial data
10.16.3 Product landscape
10.16.4 Strategic outlook
10.16.5 SWOT analysis
10.17 Triangle Compounding Pharmacies
10.17.1 Business overview
10.17.2 Financial data
10.17.3 Product landscape
10.17.4 Strategic outlook
10.17.5 SWOT analysis
10.18 Wedgewood Village Pharmacy, Inc.
10.18.1 Business overview
10.18.2 Financial data
10.18.3 Product landscape
10.18.4 Strategic outlook
10.18.5 SWOT analysis
